Comparing Lucid Diagnostics (NASDAQ:LUCD) and Alpha Tau Medical (NASDAQ:DRTS)

Lucid Diagnostics (NASDAQ:LUCD) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Volatility and Risk

Lucid Diagnostics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Lucid Diagnostics and Alpha Tau Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,418.39%	N/A	-96.99%
Alpha Tau Medical	N/A	-56.45%	-41.76%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lucid Diagnostics and Alpha Tau Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Alpha Tau Medical	2	0	2	0	2.00

Lucid Diagnostics currently has a consensus target price of $3.94, suggesting a potential upside of 196.05%. Alpha Tau Medical has a consensus target price of $8.00, suggesting a potential upside of 10.96%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Alpha Tau Medical.

Earnings and Valuation

This table compares Lucid Diagnostics and Alpha Tau Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.35 million	42.10	-$45.53 million	($1.04)	-1.28
Alpha Tau Medical	N/A	N/A	-$31.75 million	($0.52)	-13.87

Alpha Tau Medical has lower revenue, but higher earnings than Lucid Diagnostics. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

Lucid Diagnostics beats Alpha Tau Medical on 8 of the 13 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.